2024 年度，本人作为重庆山外山血液净化技术股份有限公司（以下简称"公 司"）的独立董事，严格按照《公司法》《证券法》《上市公司独立董事管理办 法》等法律法规、规范性文件以及《公司章程》《公司独立董事工作制度》的规 定和要求，本着恪尽职守、勤勉尽责的工作态度，积极出席公司股东大会、董事 会及各专门委员会会议，认真审议董事会各项议案，忠实勤勉地履行独立董事职 责，并按照规定对公司相关事项发表了独立、客观、公正的意见。现将 2024 年 度履行职责的情况报告如下： 一、独立董事基本情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域积累了 丰富的经验。本人个人工作履历、专业背景以及兼职情况如下： 陈定文，1971 年 7 月出生，中国国籍，无境外永久居留权。毕业于上海财 经大学会计学专业，硕士研究生学历，中国注册会计师、注册税务师、资产评估 师、房地产估价师、司法会计及评估鉴定等执业资格、高级会计师职称。1994 年 7 月至 1996 年 12 月任中国石油天然气股份有限公司重庆销售分公司会计； 1997 年 1 月至 2005 年 3 月任天健会计师事务所（特殊普通合伙）重庆分所审计 部经理、 ...

重庆山外山血液净化技术股份有限公司 2024 年度独立董事述职报告（姜峰） 1 2024 年度，本人作为重庆山外山血液净化技术股份有限公司（以下简称"公 司"）的独立董事，严格按照《公司法》《证券法》《上市公司独立董事管理办法》 等法律法规、规范性文件以及《公司章程》《公司独立董事工作制度》的规定和 要求，本着恪尽职守、勤勉尽责的工作态度，积极出席公司股东大会、董事会及 各专门委员会会议，认真审议董事会各项议案，忠实勤勉地履行独立董事职责， 并按照规定对公司相关事项发表了独立、客观、公正的意见。现将 2024 年度履 行职责的情况报告如下： 一、独立董事基本情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域积累了 丰富的经验。本人个人工作履历、专业背景以及兼职情况如下： 作为公司的独立董事，本人及本人直系亲属、主要社会关系均不在公司或其 附属企业任职，且未在公司关联企业任职；没有为公司或其附属企业提供财务、 法律、管理、技术等咨询服务；除独立董事津贴外，没有从公司及其主要股东或 有利害关系的机构和人员取得额外的、未予披露的其他利益，不存在影响独立性 的情况。 姜峰，1985 年 9 月至 19 ...

重庆山外山血液净化技术股份有限公司 募集资金管理制度 重庆山外山血液净化技术股份有限公司 募集资金管理制度 第一章 总则 第一条 为规范重庆山外山血液净化技术股份有限公司（以下简 称"公司"）募集资金的使用与管理，提高募集资金使用效益，切实 保护投资者利益，根据《中华人民共和国公司法》、《中华人民共和国 证券法》（以下简称"《证券法》"）、《首次公开发行股票注册管理办法 》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板 上市公司自律监管指引第 1 号——规范运作》等相关法律法规和规 范性文件以及《公司章程》的规定，结合公司实际情况，制订本制度。 第二条 本制度所称募集资金是指公司通过向不特定对象发行证 券（包括首次公开发行股票、配股、增发、发行可转换公司债券、发 行分离交易的可转换公司债券等）以及向特定对象发行证券募集的资 金，但不包括公司实施股权激励计划募集的资金。 第三条 公司董事、监事和高级管理人员应当勤勉尽责，督促公 司规范使用募集资金，自觉维护公司募集资金安全，不得参与、协助 或纵容公司擅自或变相改变募集资金用途。 公司董事会负责建立、健全本制度，以对募集资金专户存储、 使用、变更、监督 ...

重庆山外山血液净化技术股份有限公司 2024 年度独立董事述职报告（李丽山） 2024 年度，本人作为重庆山外山血液净化技术股份有限公司（以下简称"公 司"）的独立董事，严格按照《公司法》《证券法》《上市公司独立董事管理办法》 等法律法规、规范性文件以及《公司章程》《公司独立董事工作制度》的规定和 要求，本着恪尽职守、勤勉尽责的工作态度，积极出席公司股东大会、董事会及 各专门委员会会议，认真审议董事会各项议案，忠实勤勉地履行独立董事职责， 并按照规定对公司相关事项发表了独立、客观、公正的意见。现将 2024 年度履 行职责的情况报告如下： 一、独立董事基本情况 作为公司的独立董事，本人拥有专业资质及能力，在从事的专业领域积累了 丰富的经验。本人个人工作履历、专业背景以及兼职情况如下： 李丽山先生，1974 年 3 月出生，中国国籍，无境外永久居留权。法学专业， 本科学历。1993 年 8 月至 2010 年 4 月就职于西南药业股份有限公司；2010 年 4 月至 2013 年 12 月任重庆君毅律师事务所执业律师；2014 年 1 月至 2014 年 5 月 任重庆瑞月永华律师事务所执业律师；2014 年 ...

Financial Performance - The company's operating revenue for 2024 is CNY 567,274,510.17, a decrease of 17.80% compared to CNY 690,112,369.84 in 2023[19]. - Net profit attributable to shareholders for 2024 is CNY 70,886,298.12, down 63.55% from CNY 194,498,864.39 in 2023[19]. - The net profit after deducting non-recurring gains and losses for 2024 is CNY 57,177,858.38, a decrease of 67.53% compared to CNY 176,101,441.96 in 2023[19]. - The company's net profit attributable to shareholders decreased by 63.37% to CNY 0.2217 per share in 2024 compared to CNY 0.6053 in 2023[21]. - The company's comprehensive gross margin for the reporting period was 45.29%, a decrease of 4.64 percentage points year-on-year, primarily due to changes in product structure[128]. - The company reported a net profit margin of 20%, up from 18% in the previous year, reflecting improved operational efficiency[200]. Dividend and Share Repurchase - The company plans to distribute a cash dividend of 1.00 RMB per 10 shares, totaling approximately 31,964,930.50 RMB, which represents 45.09% of the net profit attributable to shareholders for the year[4]. - The total amount for cash dividends and share repurchases is 81,959,591.13 RMB, accounting for 115.62% of the net profit attributable to shareholders[5]. - The profit distribution plan is subject to approval at the 2024 annual general meeting[5]. Audit and Compliance - The company has received a standard unqualified audit report from Tianzhi International Accounting Firm[4]. - The board of directors and management have confirmed the accuracy and completeness of the annual report[3]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[7]. - The company’s governance structure complied with relevant laws and regulations, ensuring the protection of minority shareholders' rights[192]. Research and Development - Research and development expenses accounted for 9.56% of operating revenue, an increase of 4.05 percentage points from 5.51% in the previous year[21]. - The company's R&D investment increased by 42.62% compared to the previous year, reflecting a commitment to enhancing technological innovation[22]. - The company achieved a research and development investment of 54.24 million yuan, representing a year-on-year increase of 42.62%[93]. - The number of R&D personnel increased by 45.77% to 207 individuals[93]. - During the reporting period, the company applied for 15 invention patents, 28 utility model patents, and 12 design patents[90]. Market Position and Strategy - The company achieved a market share of 15.97% in the blood dialysis machine segment, ranking first among domestic brands[35]. - The company has established a comprehensive product line including blood dialysis machines and continuous blood purification devices, enhancing its market competitiveness[109]. - The company is focusing on expanding its product line, including hemodialysis machines, continuous blood purification devices, and related consumables, to establish a comprehensive blood purification industry chain[175]. - The company aims to enhance its global sales network and increase its market share in international markets, leveraging the Belt and Road Initiative[176]. Risks and Challenges - There are no significant risks that could materially affect the company's production and operations during the reporting period[3]. - The company faces risks related to the potential inability to renew medical insurance qualifications, which could impact revenue from dialysis services[129]. - The company is at risk of losing core technical personnel, which is critical for maintaining its technological advantage in the blood purification industry[118]. - The company's market share in the domestic blood purification industry remains low, with risks of underperformance in revenue growth due to insufficient market expansion efforts[126]. Innovation and Technology - The company emphasizes technology innovation through independent research and development, supported by national-level technology centers and a complete product development process[49]. - The company has developed a smart hemodialysis management system that enhances patient experience and operational efficiency, achieving over 50% improvement in management efficiency and 20 times increase in statistical efficiency[47][48]. - The company has integrated online monitoring functions for physiological parameters such as blood pressure, blood volume, blood temperature, Kt/V, and URR in its hemodialysis machines, which can assess patient treatment effects in real-time and reduce the risk of dialysis-related complications[70]. International Expansion - International sales reached 128.43 million yuan, a year-on-year growth of 29.74%[36]. - The company is focusing on expanding its market presence in Southeast Asia, targeting a 10% market share by the end of the next fiscal year[198]. - The company aims to enhance R&D investment in new products, integrating next-generation information technology and artificial intelligence to improve the intelligence level of blood purification devices and consumables[175]. Operational Efficiency - The net cash flow from operating activities for 2024 is CNY 143,147,696.51, an increase of 121.75% from CNY 64,553,561.40 in 2023[19]. - The company has implemented an ERP system to manage procurement, production, quality inspection, and inventory, ensuring product quality stability and timely delivery[52]. - The company is focusing on optimizing production processes to improve product quality and reduce costs, particularly in the development of disposable blood purification products[1]. Corporate Governance - The company held 9 board meetings during the reporting period, ensuring compliance with legal and regulatory requirements[190]. - The company’s supervisory board held 7 meetings, effectively overseeing major transactions and financial conditions[191]. - The company maintained a strong focus on investor relations, enhancing communication and feedback mechanisms with shareholders[193].

Financial Performance - The company's revenue for Q1 2025 reached ¥189,262,367.90, representing a 16.77% increase compared to ¥162,081,904.07 in the same period last year[6] - Net profit attributable to shareholders was ¥37,006,398.74, an increase of 8.10% from ¥34,232,483.34 year-on-year[6] - The company reported a basic and diluted earnings per share of ¥0.1162, a 9.11% increase from ¥0.1065 in the previous year[6] - Total operating revenue for Q1 2025 reached ¥189,262,367.90, a 16.77% increase from ¥162,081,904.07 in Q1 2024[21] - Net profit for Q1 2025 was ¥36,905,077.50, representing an increase of 9.86% compared to ¥33,575,271.86 in Q1 2024[22] - Basic and diluted earnings per share for Q1 2025 were both ¥0.1162, up from ¥0.1065 in Q1 2024[23] Cash Flow - The net cash flow from operating activities surged to ¥15,428,603.44, a significant increase of 4,614.07% compared to ¥327,288.28 in the previous year[6] - Cash flow from operating activities for Q1 2025 was ¥15,428,603.44, significantly higher than ¥327,288.28 in Q1 2024[26] - Cash inflow from operating activities totaled ¥193,040,465.61 in Q1 2025, compared to ¥133,181,171.98 in Q1 2024[25] - The ending cash and cash equivalents balance for Q1 2025 was ¥619,009,413.63, down from ¥702,935,710.65 in Q1 2024[26] Expenses and Costs - Research and development expenses totaled ¥16,427,143.12, marking a 32.20% increase from ¥12,425,971.75 in the same period last year, accounting for 8.68% of total revenue[6] - Total operating costs for Q1 2025 were ¥153,931,158.16, up 14.29% from ¥134,689,255.37 in Q1 2024[21] - The company reported a tax expense of ¥3,791,523.32 for Q1 2025, compared to ¥2,654,692.42 in Q1 2024[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥2,042,520,476.59, reflecting a 1.54% increase from ¥2,011,555,609.34 at the end of the previous year[6] - The company's total assets amounted to CNY 2,042,520,476.59, an increase from CNY 2,011,555,609.34 as of December 31, 2024, reflecting a growth of approximately 1.1%[17][20] - The company's total liabilities decreased to CNY 323,092,480.13 from CNY 333,259,232.90, representing a reduction of about 3.5%[19] - The total equity attributable to the parent company increased to CNY 1,728,293,337.34 from CNY 1,687,060,396.08, marking a growth of approximately 2.5%[20] - Cash and cash equivalents decreased to CNY 559,354,161.05 from CNY 631,440,099.36, a decline of about 11.4%[17] - The company's accounts receivable rose to CNY 117,865,716.06 from CNY 104,292,725.45, indicating an increase of approximately 13.1%[17] - Inventory levels decreased to CNY 144,847,089.77 from CNY 152,969,747.46, a decline of about 5.3%[17] - The company reported a total of CNY 1,682,142,200.16 in current assets, slightly up from CNY 1,678,045,417.97, reflecting a marginal increase of about 0.2%[18] - The non-current assets increased to CNY 360,378,276.43 from CNY 333,510,191.37, showing a growth of approximately 8.1%[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 7,938[12] - The top shareholder, Gao Guangyong, holds 24.26% of the shares, totaling 77,961,620 shares[12] Market Position - The company attributed the revenue growth to its leading position in the domestic blood purification equipment market and increased sales of self-produced consumables[11] Other Information - The company's short-term borrowings and other liabilities were not specified, indicating a focus on maintaining liquidity and managing debt levels[19] - The company has not reported any significant changes in shareholder participation in margin trading or securities lending activities[15]

重庆山外山血液浄化技术股份有限公司董事会 重庆山外山血液净化技术 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律监管 指引第1号 -- 规范运作》等要求,重庆山外山血液净化技术股份有限公司(以下简 称"公司")董事会,就公司在任独立董事陈定文先生、姜峰先生、李丽山先生的独 立性情况进行评估并出具如下专项意见: 经核查独立董事陈定文先生、姜峰先生、李丽山先生及其直系亲属和主要社会关 系人员的任职经历以及独立董事签署的相关自查文件,独立董事陈定文先生、姜峰先 生、李丽山先生不存在《上市公司独立董事管理办法》第六条不得担任独立董事的情 形,在担任公司独立董事期间,独立董事已严格遵守中国证监会和上海证券交易所的 相关规定,确保有足够的时间和精力勤勉尽责地履行职责,作出独立判断,不受公司 主要股东、实际控制人或其他与公司存在利害关系的单位或个人的影响。公司独立董 事陈定文先生、姜峰先生、李丽山先生符合《上市公司独立董事管理办法》《上海证 券交易所科创板上市公司自律监管指引第1号 -- 规范运作》中对独立董事独立性的 相关要求。 关于独立董事独立性情况的专项意见 ...

重庆山外山血液净化技术股份有限公司（以下简称"公司"）为践行"以投 资者为本"的上市公司发展理念，维护公司全体股东利益，基于对公司未来发展 前景的信心、对公司价值的认可和切实履行社会责任，公司于 2024 年 4 月 26 日在上海证券交易所披露了《2024 年"提质增效重回报"行动方案》，并于 2024 年 8 月 23 日披露了《2024 年度提质增效重回报专项行动方案的半年度评估报告》。 2024 年度，公司根据上述行动方案内容积极开展和落实相关工作，在保障投资 者权益、树立良好资本市场形象等方面取得了一定成效。 为延续 2024 年度行动方案成果，进一步提高公司质量，助力信心提振、资 本市场稳定和经济高质量发展，公司制定了 2025 年度"提质增效重回报"行动 方案。2024 年行动方案主要举措的执行、成效情况及 2025 年行动方案具体内容 阐明如下： 一、聚焦经营主业，提升核心竞争力 公司坚持以技术创新驱动为发展战略，以市场需求为导向，专注聚焦血液净 化行业，积极响应国家医疗器械高质量发展的产业政策，不断拓展产品线，形成 了血液透析机、连续性血液净化设备、血液灌流机等全系列血液净化设备，透析 器、 ...

证券代码：688410 证券简称：山外山 公告编号：2025-019 重庆山外山血液净化技术股份有限公司 关于 2024 年度募集资金存放与实际使用情况 的专项报告 1 2024 年度本公司募集资金其他变动为：(1)2024 年度募集资金账户收到的现 金管理收益、利息收入扣减手续费净额 22,740,628.45 元；(2)公司以部分暂时 闲置募集资金进行现金管理，截至 2024 年 12 月 31 日，结构性存款产品余额为 410,000,000.00 元。 二、募集资金管理情况 （一）募集资金管理制度情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据中国证券监督管理委员会《上市公司监管指引第2号——上市公司募集 资金管理和使用的监管要求》《上海证券交易所科创板上市公司自律监管指引第 1号——规范运作》《上海证券交易所科创板股票上市规则》等有关法律、法规 及相关文件的规定，重庆山外山血液净化技术股份有限公司（以下简称"公司" 或"本公司"或"山外山"）就2024年度（以下简称"报告期内"）募集资金存 放与实际使用 ...

证券代码：688410 证券简称：山外山 公告编号：2025-024 重庆山外山血液净化技术股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 重庆山外山血液净化技术股份有限公司（以下简称"公司"）本次会计 政策变更系根据中华人民共和国财政部（以下简称"财政部"）颁布的《企业会 计准则应用指南汇编 2024》《企业数据资源相关会计处理暂行规定》《企业会 计准则解释第 18 号》的相关规定进行的相应变更。 ● 本次会计政策变更无需提交公司董事会和股东大会审议，不会对公司的 财务状况、经营成果和现金流量产生重大影响，亦不存在损害公司及股东利益的 情况。 一、本次会计政策变更情况概述 （一）会计政策变更原因 2023 年 8 月 1 日，财政部颁布了《企业数据资源相关会计处理暂行规定》， 适用于符合企业会计准则相关规定确认为无形资产或存货等资产的数据资源，以 及企业合法拥有或控制的、预期会给企业带来经济利益的、但不满足资产确认条 件而未予确认的数据资源的相关会计处理，并对数据 ...